{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:17:33Z","timestamp":1775031453102,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.clbc.2015.11.001","type":"journal-article","created":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T07:22:21Z","timestamp":1447744941000},"page":"e69-e74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis"],"prefix":"10.1016","volume":"16","author":[{"given":"Marissa D.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2015.11.001_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2015.11.001_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12609-014-0155-y","article-title":"Therapeutic considerations in treating HER2-positive metastatic breast cancer","volume":"6","author":"O'Sullivan","year":"2014","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.clbc.2015.11.001_bib3","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","article-title":"Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study","volume":"30","author":"Blackwell","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2015.11.001_bib4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","volume":"15","author":"de Azambuja","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2015.11.001_bib5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S1470-2045(13)70411-X","article-title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","volume":"14","author":"Robidoux","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2015.11.001_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10549-013-2469-2","article-title":"RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer","volume":"138","author":"Moreno-Aspitia","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl","key":"10.1016\/j.clbc.2015.11.001_bib7","volume":"32","author":"Piccart-Gebhart","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2015.11.001_bib8","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1200\/JCO.2009.26.5900","article-title":"Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2\/neu-overexpressed\/amplified breast cancer is not feasible because of excessive diarrhea","volume":"28","author":"Dang","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2015.11.001_bib9","unstructured":"National Institutes of Health ClinicalTrials.gov: Chemotherapy and lapatinib or trastuzumab in treating women with her2\/neu-positive metastatic breast cancer. Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00667251. Accessed January 9, 2015."},{"key":"10.1016\/j.clbc.2015.11.001_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejca.2015.02.005","article-title":"Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage human epidermal growth factor receptor (HER2) overexpressing breast cancer","volume":"51","author":"Boyle","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2015.11.001_bib11","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1158\/1078-0432.CCR-10-0421","article-title":"Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1\/2 inhibitors in cancer patients","volume":"16","author":"Nardone","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2015.11.001_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clbc.2015.11.001_bib13","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2217\/fon.13.62","article-title":"Skin toxicity of targeted cancer agents: mechanisms and intervention","volume":"9","author":"Belum","year":"2013","journal-title":"Future Oncol"},{"key":"10.1016\/j.clbc.2015.11.001_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1242\/jcs.110.2.113","article-title":"EGF-R dependent regulation of keratinocyte survival","volume":"110","author":"Rodeck","year":"1997","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.clbc.2015.11.001_bib15","first-page":"351210","article-title":"Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management","volume":"2012","author":"Abdullah","year":"2012","journal-title":"Chemother Res Pract"},{"key":"10.1016\/j.clbc.2015.11.001_bib16","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) v4.0","year":"2009"},{"key":"10.1016\/j.clbc.2015.11.001_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","article-title":"Analysis of dermatologic events in patients with cancer treated with lapatinib","volume":"114","author":"Lacouture","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl","key":"10.1016\/j.clbc.2015.11.001_bib18","article-title":"Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)","volume":"32","author":"Iyengar","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2015.11.001_bib19","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1200\/JCO.2011.40.5241","article-title":"Randomized trial of lapatinib vs. placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer","volume":"31","author":"Guan","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2015.11.001_bib20","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"Di Leo","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2015.11.001_bib21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10549-011-1411-8","article-title":"Pilot neoadjuvant trial in HER2+ breast cancer with combination of nab-paclitaxel and lapatinib","volume":"132","author":"Kaklamani","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2015.11.001_bib22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10549-014-3126-0","article-title":"Development of prediction tools for diarrhea and rash in patients with breast cancer receiving lapatinib in combination with capecitabine","volume":"147","author":"Dranitsaris","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2015.11.001_bib23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000229751","article-title":"Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147","volume":"77","author":"Jatoi","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.clbc.2015.11.001_bib24","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2015.11.001_bib25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2015.11.001_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.clbc.2015.11.001_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-4632.2010.04791.x","article-title":"Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors","volume":"50","author":"Balagula","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clbc.2015.11.001_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2478\/raon-2013-0014","article-title":"A\u00a0review of the treatment options for skin rash induced by EGFR-targeted therapies: evidence from randomized clinical trials and a meta-analysis","volume":"47","author":"Ocvirk","year":"2013","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.clbc.2015.11.001_bib29","doi-asserted-by":"crossref","first-page":"734249","DOI":"10.1155\/2014\/734249","article-title":"Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management","volume":"2014","author":"Chanprapaph","year":"2014","journal-title":"Dermatol Res Pract"},{"issue":"suppl","key":"10.1016\/j.clbc.2015.11.001_bib30","first-page":"5087","article-title":"Treatment of cetuximab-associated cutaneous side effects using topical application of vitamin K1 cream","volume":"27","author":"Ocvirk","year":"2009","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820915002748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820915002748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:14:42Z","timestamp":1761513282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820915002748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1526820915002748"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2015.11.001","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2015.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}